Transferrin Receptor-Mediated Liposomal Drug Delivery: Recent Trends in Targeted Therapy of Cancer Publisher Pubmed



Mojaradjabali S^{1, 2} ; Mahdinloo S^{1, 2} ; Farshbaf M^{2, 3} ; Sarfraz M⁴ ; Fatahi Y⁵ ; Atyabi F⁶ ; Valizadeh H^{1, 7} Show Affiliations
Source: Expert Opinion on Drug Delivery Published:2022

Abstract

Introduction: Compared to normal cells, malignant cancer cells require more iron for their growth and rapid proliferation, which can be supplied by a high expression level of transferrin receptor (TfR). It is well known that the expression of TfR on the tumor cells is considerably higher than that of normal cells, which makes TfR an attractive target in cancer therapy. Areas covered: In this review, the primary focus is on the role of TfR as a valuable tool for cancer-targeted drug delivery, followed by the full coverage of available TfR ligands and their conjugation chemistry to the surface of liposomes. Finally, the most recent studies investigating the potential of TfR-targeted liposomes as promising drug delivery vehicles to different cancer cells are highlighted with emphasis on their improvement possibilities to become a part of future cancer medicines. Expert opinion: Liposomes as a valuable class of nanocarriers have gained much attention toward cancer therapy. From all the studies that have exploited the therapeutic and diagnostic potential of TfR on cancer cells, it can be realized that the systematic assessment of TfR ligands applied for liposomal targeted delivery has yet to be entirely accomplished. © 2022 Informa UK Limited, trading as Taylor & Francis Group.